Compare Novo Nordisk A/S (NVO) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Novo Nordisk A/S trades at $38.12 (market cap $165.31B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.67 (market cap $2.03B). The key difference: Novo Nordisk A/S is far larger — about 81.4× Direxion Daily 20 Year Treasury Bull 3X Shares's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| NVO | TMF | |
|---|---|---|
Market Cap | $165.31B | $2.03B |
Volume | 11,432,838 | 12,241,664 |
Sector | Health | Fixed Income |
52-Week High | $63.98 | $44.14 |
52-Week Low | $35.29 | $25.19 |
Typical Hold Time | 116 Days | 28 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
TMF trades at $25.23, down 0.51% with bearish technical signals from moving averages. The ETF saw increased trading volume of 5.2 million shares, indicating heightened investor interest. Key support sits at $24-25 while resistance levels are at $25-26. RSI readings below 20 suggest potential oversold conditions despite the bearish trend.
As a leveraged Treasury ETF, TMF faces interest rate sensitivity and market volatility risks. The bearish technical outlook and Federal Reserve policy uncertainty create headwinds, though oversold conditions may present tactical opportunities for investors anticipating rate cuts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
